Sarepta Therapeutics (SRPT) to Release Earnings on Wednesday

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) will be issuing its quarterly earnings data after the market closes on Wednesday, November 6th. Analysts expect the company to announce earnings of ($0.15) per share for the quarter. Investors interested in listening to the company's conference call can do so using this link.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 EPS for the quarter, beating the consensus estimate of $0.01 by $0.06. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The business had revenue of $362.90 million for the quarter, compared to analysts' expectations of $394.38 million. During the same period in the prior year, the firm earned ($0.27) earnings per share. Sarepta Therapeutics's revenue was up 38.9% compared to the same quarter last year. On average, analysts expect Sarepta Therapeutics to post $1 EPS for the current fiscal year and $10 EPS for the next fiscal year.

Sarepta Therapeutics Trading Down 1.9 %

NASDAQ:SRPT traded down $2.43 during trading hours on Wednesday, hitting $127.78. 658,047 shares of the stock were exchanged, compared to its average volume of 1,233,185. The company has a market capitalization of $12.08 billion, a P/E ratio of 1,161.64 and a beta of 0.82. The company has a quick ratio of 3.19, a current ratio of 3.90 and a debt-to-equity ratio of 1.05. The company's 50 day moving average is $128.07 and its two-hundred day moving average is $132.57. Sarepta Therapeutics has a twelve month low of $55.25 and a twelve month high of $173.25.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on SRPT. Barclays dropped their price objective on Sarepta Therapeutics from $226.00 to $203.00 and set an "overweight" rating for the company in a report on Thursday, August 8th. Jefferies Financial Group began coverage on Sarepta Therapeutics in a research note on Monday, October 21st. They set a "buy" rating and a $165.00 price objective for the company. Needham & Company LLC reiterated a "buy" rating and issued a $205.00 price objective on shares of Sarepta Therapeutics in a report on Monday, October 14th. Royal Bank of Canada restated an "outperform" rating and set a $182.00 target price on shares of Sarepta Therapeutics in a report on Monday, October 21st. Finally, Citigroup lowered their price target on Sarepta Therapeutics from $176.00 to $160.00 and set a "neutral" rating for the company in a research note on Thursday, August 8th. Two analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $182.95.

Insider Buying and Selling

In other Sarepta Therapeutics news, CFO Ian Michael Estepan sold 5,985 shares of the business's stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the transaction, the chief financial officer now owns 33,946 shares of the company's stock, valued at $4,662,822.56. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Sarepta Therapeutics news, Director Michael Andrew Chambers purchased 37,038 shares of the stock in a transaction on Friday, August 16th. The shares were purchased at an average price of $133.80 per share, with a total value of $4,955,684.40. Following the completion of the transaction, the director now directly owns 284,034 shares in the company, valued at $38,003,749.20. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Ian Michael Estepan sold 5,985 shares of the company's stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $137.36, for a total value of $822,099.60. Following the completion of the sale, the chief financial officer now owns 33,946 shares in the company, valued at $4,662,822.56. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by corporate insiders.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.